| scholarly article | Q13442814 |
| P2093 | author name string | Justin Taylor | |
| Daniel H Fowler | |||
| Paul R Massey | |||
| Miriam E Mossoba | |||
| Shoba Amarnath | |||
| Tania C Felizardo | |||
| Jason Foley | |||
| Jacopo Mariotti | |||
| Kaitlyn Ryan | |||
| Nicole Buxhoeveden | |||
| P2860 | cites work | Pentostatin in steroid-refractory acute graft-versus-host disease | Q28245825 |
| Pentostatin in chronic lymphocytic leukemia | Q28291531 | ||
| Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion | Q28507222 | ||
| An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning | Q33228033 | ||
| Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia | Q33347187 | ||
| Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin) | Q33477151 | ||
| Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. | Q33880215 | ||
| Non myeloablative "mini transplants". | Q33912414 | ||
| Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation | Q35060002 | ||
| Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo | Q35847438 | ||
| Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells | Q35995727 | ||
| Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized | Q36357551 | ||
| Animal model for immune dysfunction associated with adenosine deaminase deficiency | Q36403326 | ||
| Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity | Q36683412 | ||
| Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway | Q37002030 | ||
| Therapeutic benefit of pentostatin in severe IL-10-/- colitis | Q42705209 | ||
| DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine | Q43797685 | ||
| Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation1 | Q44591461 | ||
| A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease | Q44780698 | ||
| Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine | Q45209859 | ||
| Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388 | Q70366787 | ||
| Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells | Q71726052 | ||
| Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin | Q72089799 | ||
| Combination therapy with nucleoside analogs and alkylating agents | Q72350582 | ||
| The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice | Q72667919 | ||
| Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy | Q73436821 | ||
| CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects | Q73652703 | ||
| An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD | Q73803732 | ||
| Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation | Q78039826 | ||
| Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity | Q93729850 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 620-631 | |
| P577 | publication date | 2010-12-03 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection | |
| P478 | volume | 17 |
| Q37206443 | A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
| Q28085551 | Advances in anticancer immunotoxin therapy |
| Q37397003 | Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage. |
| Q38105635 | Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation |
| Q36117735 | High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses |
| Q35262181 | Immunopathological changes in the brain of immunosuppressed mice experimentally infected with Toxocara canis |
| Q37684156 | Immunotoxin Therapy for Lung Cancer |
| Q36435150 | MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice. |
| Q52603959 | Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment. |
| Q35023967 | Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts |
| Q36341861 | Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. |
| Q38170502 | Rapamycin-resistant effector T-cell therapy. |
Search more.